IYH:NYE-iShares U.S. Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 65.58

Change

-0.16 (-0.24)%

Market Cap

N/A

Volume

0.44M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.26 (-0.17%)

USD 42.19B
FHLC Fidelity® MSCI Health Care In..

-0.02 (-0.03%)

USD 3.02B
FXH First Trust Health Care AlphaD..

-0.02 (-0.02%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.11 (-0.12%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.09 (-0.38%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.40 (+1.07%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.43 (+0.44%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.05 (-0.17%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.19 (-0.29%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.22 (+0.76%)

USD 0.01B

ETFs Containing IYH

RXD ProShares UltraShort Heal.. 10.32 % 0.77 %

-0.03 (-0.32%)

N/A
RXD ProShares UltraShort Heal.. 10.32 % 0.95 %

-0.03 (-0.32%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.55% 81% B- 73% C
Dividend Return 0.51% 67% D+ 10% F
Total Return 15.06% 81% B- 68% D+
Trailing 12 Months  
Capital Gain 18.20% 67% D+ 64% D
Dividend Return 1.27% 78% C+ 18% F
Total Return 19.47% 76% C+ 58% F
Trailing 5 Years  
Capital Gain 68.61% 90% A- 79% B-
Dividend Return 6.42% 78% C+ 19% F
Total Return 75.03% 95% A 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 9.11% 86% B+ 67% D+
Dividend Return 10.11% 90% A- 63% D
Total Return 1.00% 79% B- 22% F
Risk Return Profile  
Volatility (Standard Deviation) 12.62% 71% C- 71% C-
Risk Adjusted Return 80.12% 86% B+ 91% A-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike